HULTA PHARMA | S V GLOBAL | HULTA PHARMA/ S V GLOBAL |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -15.4 | 76.8 | - | View Chart |
P/BV | x | - | 2.9 | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
HULTA PHARMA S V GLOBAL |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
HULTA PHARMA Mar-23 |
S V GLOBAL Mar-23 |
HULTA PHARMA/ S V GLOBAL |
5-Yr Chart Click to enlarge
|
||
High | Rs | 10 | 74 | 14.1% | |
Low | Rs | 3 | 40 | 7.4% | |
Sales per share (Unadj.) | Rs | 0 | 3.8 | 0.0% | |
Earnings per share (Unadj.) | Rs | -0.4 | 0.1 | -716.8% | |
Cash flow per share (Unadj.) | Rs | -0.4 | 0.3 | -157.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -1.2 | 35.8 | -3.4% | |
Shares outstanding (eoy) | m | 7.45 | 18.08 | 41.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0 | 15.0 | - | |
Avg P/E ratio | x | -15.7 | 959.1 | -1.6% | |
P/CF ratio (eoy) | x | -15.7 | 210.6 | -7.5% | |
Price / Book Value ratio | x | -5.6 | 1.6 | -351.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 50 | 1,033 | 4.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1 | 9 | 12.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 0 | 69 | 0.0% | |
Other income | Rs m | 0 | 2 | 0.0% | |
Total revenues | Rs m | 0 | 71 | 0.0% | |
Gross profit | Rs m | -3 | 13 | -20.2% | |
Depreciation | Rs m | 0 | 4 | 0.0% | |
Interest | Rs m | 1 | 0 | 611.1% | |
Profit before tax | Rs m | -3 | 11 | -28.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 10 | 0.0% | |
Profit after tax | Rs m | -3 | 1 | -295.4% | |
Gross profit margin | % | 0 | 19.1 | - | |
Effective tax rate | % | 0 | 90.3 | -0.0% | |
Net profit margin | % | 0 | 1.6 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 0 | 565 | 0.1% | |
Current liabilities | Rs m | 0 | 8 | 1.4% | |
Net working cap to sales | % | 0 | 811.7 | - | |
Current ratio | x | 3.6 | 72.4 | 5.0% | |
Inventory Days | Days | 0 | 18 | - | |
Debtors Days | Days | 0 | 18,386 | - | |
Net fixed assets | Rs m | 0 | 96 | 0.3% | |
Share capital | Rs m | 75 | 90 | 82.4% | |
"Free" reserves | Rs m | -83 | 557 | -15.0% | |
Net worth | Rs m | -9 | 647 | -1.4% | |
Long term debt | Rs m | 10 | 2 | 525.3% | |
Total assets | Rs m | 1 | 662 | 0.1% | |
Interest coverage | x | -4.8 | 123.8 | -3.9% | |
Debt to equity ratio | x | -1.1 | 0 | -38,040.1% | |
Sales to assets ratio | x | 0 | 0.1 | 0.0% | |
Return on assets | % | -361.5 | 0.2 | -205,326.6% | |
Return on equity | % | 35.6 | 0.2 | 21,416.5% | |
Return on capital | % | -425.6 | 1.7 | -24,811.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -3 | 9 | -37.9% | |
From Investments | Rs m | NA | -10 | -0.0% | |
From Financial Activity | Rs m | 3 | 2 | 171.7% | |
Net Cashflow | Rs m | 0 | 1 | -2.9% |
Indian Promoters | % | 0.0 | 68.9 | - | |
Foreign collaborators | % | 56.3 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.1 | 4.1 | 26.0% | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 43.7 | 31.1 | 140.4% | |
Shareholders | 3,820 | 6,552 | 58.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare HULTA PHARMA With: DLF DB REALTY PRESTIGE ESTATES PSP PROJECTS NBCC (INDIA)
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | HULTA PHARMA | S V GLOBAL | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 4.86% | 3.48% | 0.45% |
1-Month | -15.75% | 1.02% | 2.55% |
1-Year | 58.32% | 85.71% | 56.14% |
3-Year CAGR | 24.48% | 45.16% | 15.22% |
5-Year CAGR | 0.53% | 10.03% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the HULTA PHARMA share price and the S V GLOBAL share price.
Moving on to shareholding structures...
The promoters of HULTA PHARMA hold a 56.3% stake in the company. In case of S V GLOBAL the stake stands at 68.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of HULTA PHARMA and the shareholding pattern of S V GLOBAL.
Finally, a word on dividends...
In the most recent financial year, HULTA PHARMA paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
S V GLOBAL paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of HULTA PHARMA, and the dividend history of S V GLOBAL.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.